COVID-19 Trials at the Minneapolis VA Health Care System

January 15, 2021

In response to the COVID-19 pandemic, the Minneapolis VA Health Care System participates in clinical trials aimed at identifying new treatments for COVID-19. These trials are supported by the National Institutes of Health and Department of Veterans Affairs. ITAC (Inpatient Treatment with Anti-Coronavirus Immunoglobulin; NCT04546581) tests the efficacy of a COVID-19 antibody infusion prepared from multiple antibody donors who have recovered from COVID-19. Therapeutics for Inpatients with COVID-19 (TICO; NCT04501978) tests the efficacy of COVID-19 monoclonal antibodies, which are specific antibodies made in the laboratory rather than collected from patients. Both studies have research sites in multiple locations (both VA and non-VA) in the US and other countries around the world. The data coordinating center for these studies is at the University of Minnesota School of Public Health. The Minneapolis VA COVID research team, led by Dr. Ken Kunisaki continues to assess new studies that seek to improve the prevention, treatment, and successful recovery from COVID-19.